AstraZeneca has entered an exclusive licence agreement with bio-platform company Alteogen, involving the latter’s ...

Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to acquire antibody-drug conjugate expert Araris Biotech. WuXi AppTec ...

AstraZeneca, a global, science-led biopharmaceutical company, and Alteogen Inc., a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

signed a deal worth up to $300 million with Alteogen to develop a subcutaneous version of the drug. The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have ...

Alteogen Inc. signed its first billion-dollar partnership this year for ALT-B4 technology through two separate contracts with Astrazeneca plc’s U.K.- and U.S.-based Medimmune subsidiaries worth up to ...